July 24th 2024
Margins < 1 mm also do not increase the risk of cutaneous squamous cell carcinoma recurrence risk if the galea aponeurotica is not involved.
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Dermatologists take a hike in the name of skin cancer
April 14th 2016Dermatologists attending the annual meeting for the Florida Society of Dermatology and Dermatologic Surgery, in Naples, took a break from meeting sessions and presentations to hike a three-mile stretch of the beach wearing sun protective clothes and sunscreen, and talking with beachgoers about skin cancer recognition and prevention.
Clarifying ingenol labeling changes
February 1st 2016Concerns have been raised over an FDA Drug Safety Communication about spontaneously submitted adverse reactions in patients using this topical treatment for actinic keratosis as well as labeling changes that were implemented because of those reports. One expert offers perspective.
Advanced melanoma Tx options expanding quickly
January 29th 2016The medical landscape has changed dramatically for advanced melanoma since 2011, with both individual and combination therapy regimens gaining approval in even recent months. While modern genomics knowledge and knowledge of the immune system have brought about significant improvements in response and longer survival periods for some patients, there is still no cure.
Melanoma risk significant among pregnant women
January 21st 2016Study finds women diagnosed with malignant melanoma during their pregnancy or within one year of giving birth were more than five times more likely to die than women who weren't pregnant. Routine skin examinations may need to be included as part of postpartum appointments.
Imaging technologies improve melanoma diagnosis
January 14th 2016While highly sensitive technology is important for detecting melanoma, methods with poor sensitivity can lead to unnecessary biopsies, treatments, cost, as well as morbidity. Several technologies are available to improve sensitivity and specificity, some of which are used as second-level tests.
Cutting edge techniques provide options for skin cancer
January 13th 2016New technologies for managing skin cancer were a topic of discussion at a scientific session at the American Society for Dermatologic Surgery’s 2015 annual meeting in Chicago in October. Seaver L. Soon, M.D., division of dermatology and dermatologic surgery at Scripps Clinic, La Jolla, Calif., was one of the moderators for the scientific discussion titled, “The Cutting Edge: New Technologies for Managing Skin Cancer.” Learn more
Viruses may lead to skin disease, cancer
October 6th 2015It’s believed that viruses cause 15-20% of all cancer cases worldwide. New technologies have helped illuminate hundreds of new viruses and researchers are only beginning to understand how those resident in the skin may cause dermatologic disorders
Evidence-based guidelines for managing challenging NMSC
August 17th 2015Ongoing research is trying to identify strategies for overcoming resistance of advanced basal cell carcinoma to targeted therapy with a Hedgehog inhibitor. High level evidence to support adjuvant radiotherapy for high-risk non-melanoma skin cancers is lacking, but certain patients warrant evaluation by a multidisciplinary tumor board and treatment with adjuvant radiotherapy based on their risk for recurrence.